ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2150

Comparative Effectiveness Of Pharmacological Interventions For Knee Osteoarthritis: A Network Meta-Analysis

Raveendhara R. Bannuru1, Timothy E. McAlindon2, John B. Wong3, David Kent4 and Christopher Schmid5, 1Rheumatology, Tufts Medical Center, Boston, MA, 2Division of Rheumatology, Tufts Medical Center, Boston, MA, 3Medicine/Clinical Decision Making, Tufts Medical Center, Boston, MA, 4Medicine, Tufts Medical Center, Boston, MA, 5Evidence-Based Practice Center, Brown University, Providence, RI

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: OA and meta-analysis

  • Tweet
  • Email
  • Print
Session Information

Title: Osteoarthritis - Clinical Aspects II: Symptoms and Therapeutics in Osteoarthritis.

Session Type: Abstract Submissions (ACR)

Background/Purpose: With the rapidly aging US population and obesity epidemic, the prevalence of knee osteoarthritis (OA) is increasing exponentially. Although a wide variety of symptomatic interventions are available, head to head comparisons are limited, and no study compares all of the treatment options against each other.

To date, we have relied on traditional meta-analysis, which only provides the relative merits of options compared directly in randomized controlled trials (RCTs) for a given condition. Network meta-analysis—an innovative approach for comparing multiple interventions in a single analysis- combines direct (head to head) and indirect (through a common comparator) evidence to increase power and precision for the effect estimates and also assigns probabilities of superiority. This approach can determine the relative comparative effectiveness of interventions that have never been compared directly in a single trial. 

Methods: We searched Medline, EMBASE, Web of Science and Cochrane Database from inception to April 2013 with no language restrictions and actively sought unpublished data. We included RCTs conducted in adults with knee OA comparing two or more of the following most widely prescribed treatments: acetaminophen, non-selective NSAIDs (diclofenac, ibuprofen, naproxen), Cox-2 selective NSAIDs (celecoxib), intra-articular (IA) corticosteroids, IA hyaluronic acid, oral placebo and IA placebo. We calculated effect sizes for pain and function for each study at 12 weeks from baseline. We performed network meta-analysis using a Bayesian random effects model with non-informative priors.

Results: Of the 127 eligible RCTs, 124 reported pain and 72 reported function outcomes. These trials included 29,842 participants with an age range of 45-75 years (Figure 1). The proportion of women ranged from 28% – 100%. For pain, all treatments were better than oral placebo and all were better significantly except for IA placebo (Figure 2). For function, oral treatments had effect sizes similar to pain, but IA treatments had a smaller effect size though comparable to oral treatments.

Conclusion: For knee OA pain, IA treatments were more efficacious than oral treatments may be because of the integrated IA placebo effect. Both cox-2 selective and non-selective NSAIDs were substantially better than acetaminophen. This information along with the safety profile and relative cost would be helpful for clinicians in choosing care tailored to individual patient. This novel method may be of additional value for the treatment guideline groups, who would like to weigh multiple interventions against a common comparison.  

 


Disclosure:

R. R. Bannuru,
None;

T. E. McAlindon,

NIH,

2;

J. B. Wong,
None;

D. Kent,
None;

C. Schmid,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-effectiveness-of-pharmacological-interventions-for-knee-osteoarthritis-a-network-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology